加拿大住院成人中非菌血症性和菌血症性肺炎链球菌社区获得性肺炎的重新校准估计:2010至2017年及扩展谱血清型特异性尿抗原检测法的应用
该研究基于2010至2017年加拿大住院成人主动监测数据,采用培养和尿抗原检测(UAD)及血清分型,重新估计肺炎链球菌社区获得性肺炎(pCAP)和侵袭性肺炎链球菌病(IPD)负担。在8912例CAP病例中检出1264例(14.2%)pCAP,其中非菌血症性811例(64.1%)、菌血症性455例(35.9%)。作者认为,在PCV13儿童免疫或成人PPV23使用群体保护不足的情况下,该研究支持成人直接接种PCV13或更高价结合疫苗以减少pCAP和IPD的残余负担。
要点
- 8912例CAP中pCAP占14.2%(1264例),非菌血症性占64.1%(811例),菌血症性占35.9%(455例)。
- 65岁及以上成人占非菌血症性pCAP的54.5%、菌血症性pCAP的41.4%和IPD的48.6%。
- PCV13血清型在2010至2014年间下降后于2015至2017年平台期,血清型3持续存在。
核心结论
- pCAP(菌血症性和非菌血症性)与IPD的监测均重要,因其趋势可能随时间不同。
- 在PCV13儿童免疫或成人PPV23使用群体保护不足的情况下,该研究支持成人直接接种PCV13或更高价结合疫苗以减少pCAP和IPD的残余负担。
研究设计与样本
- 研究为2010至2017年加拿大住院成人肺炎链球菌社区获得性肺炎(pCAP)和侵袭性肺炎链球菌病(IPD)的主动监测。
- 采用培养(血液和痰)和尿抗原检测(UAD)检测肺炎链球菌,并用Quellung、PCR或PCV13和PPV23(非PCV13)特异性UAD进行血清分型。
- 共识别11129例CAP病例和216例IPD(非CAP)病例,其中8912例CAP病例进行了肺炎链球菌实验室检测。
主要发现
- 8912例CAP病例中检出1264例(14.2%)pCAP,其中非菌血症性811例(64.1%)、菌血症性455例(35.9%)。
- 65岁及以上成人占非菌血症性pCAP的54.5%、菌血症性pCAP的41.4%和IPD病例的48.6%;50至64岁成人分别占30.3%、33.1%和29.9%。
- pCAP中PCV13血清型在2010至2014年间因血清型7F和19A下降而减少,2015至2017年平台期且血清型3持续存在。
- 研究后期非菌血症性pCAP占主导,PPV23(非PCV13)血清型从2015至2017年增加,最常见为血清型22F、11A和9N。
- 与非线性pCAP相比,pCAP病例更可能入住重症监护室和需要机械通气;这些结局和死亡率在菌血症性pCAP和IPD中比非菌血症性pCAP更常见。
临床怎么用
- 作者认为,在PCV13儿童免疫或成人PPV23使用群体保护不足的情况下,该研究支持成人直接接种PCV13或更高价结合疫苗以减少pCAP和IPD的残余负担。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE(S): In the context of age- and risk-based pneumococcal vaccine recommendations in Canada, this study presents updated data from active surveillance of pneumococcal community acquired pneumonia (pCAP) and invasive pneumococcal disease (IPD) in hospitalized adults from 2010 to 2017. METHODS: S. pneumoniae was detected using culture (blood and sputum), and urine antigen detection (UAD). Serotyping was performed with Quellung, PCR, or using the PCV13- and PPV23 (non-PCV13)-specific UADs. Laboratory results, demographic, and outcome data were categorized by age (16-49, 50-64, and 65 + ) and by disease [non-bacteremic pCAP, bacteremic pCAP, and IPD(non-CAP)]. RESULTS: 11,129 CAP cases and 216 cases of IPD (non-CAP) were identified. Laboratory testing for S. pneumoniae was performed in 8912 CAP cases, identifying 1264 (14.2%) as pCAP. Of pCAP cases, 811 (64.1%) were non-bacteremic and 455 (35.9%) were bacteremic. Adults 65 + years represented 54.5% of non-bacteremic pCAP, 41.4% of bacteremic pCAP, and 48.6% of IPD cases. Adults 50-64 years contributed 30.3%, 33.1%, and 29.9%, respectively. In pCAP, PCV13 serotypes declined between 2010 and 2014 due to declines in serotypes 7F and 19A, then plateaued from 2015 to 2017 with persistence of serotype 3. In later study years, non-bacteremic pCAP was predominant, and PPV23 (non-PCV13) serotypes increased from 2015 to 2017, with serotypes 22F, 11A, and 9 N being most frequently identified. Compared to non-pCAP, pCAP cases were more likely to be admitted to intensive care units and require mechanical ventilation. These outcomes and mortality were more common in bacteremic pCAP and IPD, versus non-bacteremic pCAP. CONCLUSION(S): Along with IPD, pCAP surveillance (bacteremic and non-bacteremic) is important as their trends may differ over time. With insufficient herd protection from PCV13 childhood immunization, or use of PPV23 in adults, this study supports direct adult immunization with PCV13 or higher valency conjugate vaccines to reduce the residual burden of pCAP and IPD.
引用
- LeBlanc JJ, ElSherif M, Ye L, et al. Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay. Vaccine. 2022. PMID: 35315326. doi:10.1016/j.vaccine.2022.02.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。